Efficacy News and Research

RSS

Research finds stronger weapon against leprosy and tuberculosis

In many parts of the world, leprosy and tuberculosis live side-by-side. Worldwide there are approximately 233,000 new cases of leprosy per year, with nearly all of them occurring where tuberculosis is endemic.

20 Aug 2014

Research validates Myc inhibition as effective therapeutic strategy for glioma

Research led by the Vall d'Hebron Institute of Oncology (VHIO) evidence the most conclusive preclinical results to-date validating Myc inhibition as a therapeutic strategy in glioma - a highly agressive tumor type that notoriously outsmarts current anti-cancer therapies.

19 Aug 2014

Actavis reports positive results from ceftazidime-avibactam Phase III studies in cIAI patients

Actavis plc today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections.

19 Aug 2014

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen (NASDAQ: AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints.

19 Aug 2014

Globavir plans to seek approval, launch novel drug for treatment of Ebola infection

Globavir Biosciences, Inc., a biotechnology company developing therapeutics to treat infectious diseases, has announced intentions to develop its lead drug candidate, GBV006, for the treatment of the current Ebola Virus outbreak in West Africa. Globavir will seek approval for the use of GBV006, a combination of Food and Drug Administration approved drugs, through an established compassionate use regulatory pathway.

19 Aug 2014

Lilly and Boehringer Ingelheim's Basaglar (insulin glargine injection) gets FDA's tentative approval

The U.S. Food and Drug Administration today granted tentative approval for Basaglar (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes.

19 Aug 2014

New contact lens microbiology workshop aims at preventing Acanthamoeba keratitis

The American Academy of Ophthalmology today announced a contact lens microbiology workshop on Sept. 12 aimed at preventing Acanthamoeba keratitis, a rare infection among contact lens wearers that causes severe eye pain, redness, light sensitivity and potential vision loss.

18 Aug 2014

ITS develops new T cell vaccine to protect humans from seasonal and pandemic influenza A

Immune Targeting Systems, specializing in the development of novel T cell immune therapies, has been developing an exciting new T cell vaccine (FlunisynTM) designed to protect humans from all strains of seasonal and pandemic influenza A.

18 Aug 2014

FDA-approved drug eliminates immune cells that destroys hair follicles in people with alopecia areata

Researchers at Columbia University Medical Center (CUMC) have identified the immune cells responsible for destroying hair follicles in people with alopecia areata, a common autoimmune disease that causes hair loss, and have tested an FDA-approved drug that eliminated these immune cells and restored hair growth in a small number of patients.

18 Aug 2014

New therapeutic strategy to combat common genetic risk factor for ALS, FTD

A team of researchers at Mayo Clinic and The Scripps Research Institute in Florida have developed a new therapeutic strategy to combat the most common genetic risk factor for the neurodegenerative disorders amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and frontotemporal dementia (FTD).

15 Aug 2014

FDA approves BELSOMRA® (suvorexant) for the treatment of insomnia

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA® (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep. BELSOMRA (pronounced bell-SOM-rah) is a highly selective antagonist for orexin receptors.

15 Aug 2014

Injections of anaerobic bacteria can shrink tumors in rats, dogs and human

Deep within most tumors lie areas that remain untouched by chemotherapy and radiation. These troublesome spots lack the blood and oxygen needed for traditional therapies to work, but provide the perfect target for a new cancer treatment using bacteria that thrive in oxygen-poor conditions.

14 Aug 2014

Healthy men participating in Prostate Cancer Prevention Trial are most likely to undergo biopsy

Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all steps of the clinical trial are most likely to undergo a biopsy, according to a study published in Cancer Epidemiology, Biomarkers and Prevention - a journal of the American Association for Cancer Research.

14 Aug 2014

Reducing brain levels of tau protein effectively blocks development of childhood epilepsy

Researchers at the Gladstone Institutes have shown that reducing brain levels of the protein tau effectively blocks the development of disease in a mouse model of Dravet syndrome, a severe intractable form of childhood epilepsy.

14 Aug 2014

Umeclidinium/vilanterol outperforms monotherapies in COPD

A combination of umeclidinium and vilanterol is more effective than each drug as monotherapy for the treatment of chronic obstructive pulmonary disease, research indicates.

13 Aug 2014

Treatment outcomes in metaanalyses may differ and result in major alterations

Depending on the analysis strategy used, estimating treatment outcomes in metaanalyses may differ and may result in major alterations in the conclusions derived from the analysis, according to a study in the August 13 issue of JAMA.

13 Aug 2014

Supermint fluoride toothpaste receives American Dental Association Seal of Acceptance

Hello is thrilled to announce that its supermint fluoride toothpaste has officially been awarded the American Dental Association (ADA) Seal of Acceptance. Recognized by dentists and consumers alike as the gold standard for U.S. oral care, the seal acknowledges that the product has met ADA guidelines for fluoride-containing toothpaste used for the control of tooth decay.

13 Aug 2014

Only 52% of women receive low-cost treatment to prevent babies death

A major international study of more than 303 000 births in 29 low-income and middle-income countries has found that only half (52%) of women who are eligible to receive a simple, effective, low-cost treatment to prevent death and disability in their newborn babies are getting it.

13 Aug 2014

Canadian government to donate experimental vaccine to combat Ebola virus

The Honourable Rona Ambrose, Minister of Health, today announced that the Government of Canada will donate doses of an experimental Ebola vaccine developed by the Public Health Agency of Canada to the World Health Organization (WHO) in its role as an international coordinating body in responding to the ongoing Ebola outbreak in West Africa.

13 Aug 2014

First peer-reviewed comprehensive expert guidance on the use of neurostimulation for pain

Reflecting groundbreaking international consensus regarding a group of rapidly evolving medical interventions for chronic pain, the International Neuromodulation Society announced it will soon publish the first peer-reviewed comprehensive expert guidance on the appropriate use of neurostimulation for pain.

12 Aug 2014

Efficacy News and Research

Research finds stronger weapon against leprosy and tuberculosis

Research validates Myc inhibition as effective therapeutic strategy for glioma

Actavis reports positive results from ceftazidime-avibactam Phase III studies in cIAI patients

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Globavir plans to seek approval, launch novel drug for treatment of Ebola infection

Lilly and Boehringer Ingelheim's Basaglar (insulin glargine injection) gets FDA's tentative approval

New contact lens microbiology workshop aims at preventing Acanthamoeba keratitis

ITS develops new T cell vaccine to protect humans from seasonal and pandemic influenza A

FDA-approved drug eliminates immune cells that destroys hair follicles in people with alopecia areata

New therapeutic strategy to combat common genetic risk factor for ALS, FTD

FDA approves BELSOMRA® (suvorexant) for the treatment of insomnia

Injections of anaerobic bacteria can shrink tumors in rats, dogs and human

Healthy men participating in Prostate Cancer Prevention Trial are most likely to undergo biopsy

Reducing brain levels of tau protein effectively blocks development of childhood epilepsy

Umeclidinium/vilanterol outperforms monotherapies in COPD

Treatment outcomes in metaanalyses may differ and result in major alterations

Supermint fluoride toothpaste receives American Dental Association Seal of Acceptance

Only 52% of women receive low-cost treatment to prevent babies death

Canadian government to donate experimental vaccine to combat Ebola virus

First peer-reviewed comprehensive expert guidance on the use of neurostimulation for pain

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News